JD Health's stock surged 5.11% in pre-market trading on Wednesday, driven by the company's robust first-quarter financial results and a newly announced share repurchase program.

The company reported Q1 revenue of RMB 19.468 billion, a 17% year-over-year increase, while operating profit jumped 70.4% to RMB 1.825 billion. On a non-IFRS basis, operating profit rose 48% to RMB 1.94 billion. Additionally, JD Health's board approved a plan to repurchase up to $1 billion worth of shares over the next 48 months, signaling strong confidence in the company's long-term value.

Business developments also contributed to positive sentiment, including the launch of over 30 new drugs, strategic partnerships with major pharmaceutical firms, and significant growth in AI-driven medical services, with user numbers already surpassing the full-year total from the prior year.